PL3827005T3 - Pirydopirymidyny jako inhibitory receptora histaminowego h4 - Google Patents

Pirydopirymidyny jako inhibitory receptora histaminowego h4

Info

Publication number
PL3827005T3
PL3827005T3 PL19742760.2T PL19742760T PL3827005T3 PL 3827005 T3 PL3827005 T3 PL 3827005T3 PL 19742760 T PL19742760 T PL 19742760T PL 3827005 T3 PL3827005 T3 PL 3827005T3
Authority
PL
Poland
Prior art keywords
pyridopyrimidines
histamine
receptor inhibitors
inhibitors
receptor
Prior art date
Application number
PL19742760.2T
Other languages
English (en)
Inventor
Gonzalo HERNÁNDEZ HERRERO
Neftalí GARCÍA DOMÍNGUEZ
Arturo ZAZPE ARCE
Roberto Olivera Tizne
Bárbara NOVERGES PEDRO
Reyes CORCÓSTEGUI VIVAR
Paloma Tato Cerdeiras
Original Assignee
Faes Farma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma, S.A. filed Critical Faes Farma, S.A.
Publication of PL3827005T3 publication Critical patent/PL3827005T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL19742760.2T 2018-07-25 2019-07-24 Pirydopirymidyny jako inhibitory receptora histaminowego h4 PL3827005T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382559 2018-07-25
PCT/EP2019/069905 WO2020020939A1 (en) 2018-07-25 2019-07-24 Pyridopyrimidines as histamine h4-receptor inhibitors

Publications (1)

Publication Number Publication Date
PL3827005T3 true PL3827005T3 (pl) 2022-11-28

Family

ID=63207688

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19742760.2T PL3827005T3 (pl) 2018-07-25 2019-07-24 Pirydopirymidyny jako inhibitory receptora histaminowego h4

Country Status (29)

Country Link
US (1) US12492199B2 (pl)
EP (1) EP3827005B1 (pl)
JP (1) JP7093462B2 (pl)
KR (1) KR102603203B1 (pl)
CN (1) CN112739699B (pl)
AU (1) AU2019310889B2 (pl)
BR (1) BR112021001270A2 (pl)
CA (1) CA3107556C (pl)
CL (1) CL2021000184A1 (pl)
CO (1) CO2021001925A2 (pl)
DK (1) DK3827005T3 (pl)
EA (1) EA202190339A1 (pl)
EC (1) ECSP21010874A (pl)
ES (1) ES2929227T3 (pl)
HR (1) HRP20221250T1 (pl)
HU (1) HUE059824T2 (pl)
LT (1) LT3827005T (pl)
MA (1) MA53372B1 (pl)
MX (1) MX2021000966A (pl)
MY (1) MY206632A (pl)
PE (1) PE20211638A1 (pl)
PH (1) PH12021550143A1 (pl)
PL (1) PL3827005T3 (pl)
PT (1) PT3827005T (pl)
RS (1) RS63661B1 (pl)
SA (1) SA521421098B1 (pl)
SG (1) SG11202100575QA (pl)
WO (1) WO2020020939A1 (pl)
ZA (1) ZA202101092B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014116A (es) * 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
JP2023084709A (ja) * 2020-04-28 2023-06-20 Meiji Seikaファルマ株式会社 ヒスタミンh4受容体調節作用を有する新規二環化合物
WO2026062171A1 (en) 2024-09-20 2026-03-26 Faes Farma, S.A. Pyridopyrimidine derivative as histamine receptor inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002434A (es) 2004-08-31 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
RU2011116928A (ru) * 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
US8481732B2 (en) 2009-03-20 2013-07-09 Incyte Corporation Substituted heterocyclic compounds
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
WO2013060881A1 (en) 2011-10-27 2013-05-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Pyridopyrimidines and their therapeutic use
EA030253B1 (ru) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Азахиназолиновые ингибиторы атипичной протеинкиназы c
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents
WO2018190778A1 (en) 2017-04-12 2018-10-18 Thammasat University Inspection procedure of the authenticity of brand-named leather bag

Also Published As

Publication number Publication date
US12492199B2 (en) 2025-12-09
KR20210038909A (ko) 2021-04-08
WO2020020939A1 (en) 2020-01-30
ES2929227T3 (es) 2022-11-25
EP3827005A1 (en) 2021-06-02
BR112021001270A2 (pt) 2021-04-20
SA521421098B1 (ar) 2024-02-08
MA53372B1 (fr) 2022-10-31
PE20211638A1 (es) 2021-08-24
RS63661B1 (sr) 2022-11-30
CA3107556A1 (en) 2020-01-30
EA202190339A1 (ru) 2021-05-20
JP2021531304A (ja) 2021-11-18
US20210300922A1 (en) 2021-09-30
MA53372A (fr) 2021-06-02
SG11202100575QA (en) 2021-02-25
EP3827005B1 (en) 2022-08-17
PH12021550143A1 (en) 2021-09-13
CL2021000184A1 (es) 2021-07-09
HRP20221250T1 (hr) 2022-12-09
CO2021001925A2 (es) 2021-03-08
NZ773053A (en) 2023-10-27
CN112739699B (zh) 2023-11-28
JP7093462B2 (ja) 2022-06-29
MY206632A (en) 2024-12-27
AU2019310889A1 (en) 2021-03-11
PT3827005T (pt) 2022-11-04
AU2019310889B2 (en) 2022-03-31
CA3107556C (en) 2022-10-25
CN112739699A (zh) 2021-04-30
KR102603203B1 (ko) 2023-11-16
MX2021000966A (es) 2021-07-06
DK3827005T3 (da) 2022-09-19
LT3827005T (lt) 2022-11-10
ECSP21010874A (es) 2021-03-31
HUE059824T2 (hu) 2023-01-28
ZA202101092B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
SG11202106520VA (en) Kif18a inhibitors
IL277006A (en) CD73 inhibitors
ZA201905811B (en) Novel inhibitors
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
IL304348A (en) cd73 inhibitors
IL277455A (en) History of aminopyrimidines as CTPS1 inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
HUE072504T2 (hu) CD73-inhibitorok
ZA201907136B (en) Ip6k inhibitors
IL276013A (en) pi4kiiibeta inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en) Inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
ZA202101092B (en) Pyridopyrimidines as histamine h4-receptor inhibitors
GB201807845D0 (en) Kinase Inhibitors
GB201721465D0 (en) Inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors